Skip to main content

Diabetes and Metabolism

The Diabetes and Metabolism Research Group is search is lead by Dr. Rafael Simó (Hirsch index:54), Head of the Endocrinology Department, Professor of Medicine & Endocrinology at UAB and current President of the European Association for the Study of Diabetes-Eye Complications. The group consists of 7 senior clinical investigators, 4 basic post-doctoral researchers, 4 pre-doc researchers, 3 laboratory technicians and one coordinator of clinical assays.  

The group belongs to “CIBER” of Diabetes and Associated Metabolic Diseases (CIBERDEM. ISCIII) and has been recognized as consolidated group by the Generalitat de Catalunya (AQU/AGAUR).

Since 2014 this group has been qualified as outstanding in the evaluations performed by the ANEP, CIBERDEM and the external Scientific Advisory Board of VHIR. 

The main lines of research are:

  • Complications of diabetes (in particular diabetic retinopathy)
  • Obesity and its co-morbidities
  • Type 2 diabetes and cognitive impairment
  • Thyroid diseases
  • Hospital Nutrition. 

Team

Pablo Sancho Diaz

Pablo Sancho Diaz

Research technician
Diabetes and Metabolism
Read more
Pedro Alejandro Gil Millán

Pedro Alejandro Gil Millán

Predoctoral researcher
Diabetes and Metabolism
Read more
Alba Rojano Toimil

Alba Rojano Toimil

Predoctoral researcher
Diabetes and Metabolism
Read more
Alejandra Planas Vilaseca

Alejandra Planas Vilaseca

Predoctoral researcher
Diabetes and Metabolism
Read more
Ana Maria Ortiz de Urbina Olive

Ana Maria Ortiz de Urbina Olive

Research assistant
Diabetes and Metabolism
Read more
Angel Michael Ortiz Zúñiga

Angel Michael Ortiz Zúñiga

Postdoctoral researcher
Diabetes and Metabolism
Read more
Pablo Sancho Diaz

Pablo Sancho Diaz

Research technician
Diabetes and Metabolism
Read more
Pedro Alejandro Gil Millán

Pedro Alejandro Gil Millán

Predoctoral researcher
Diabetes and Metabolism
Read more
Alba Rojano Toimil

Alba Rojano Toimil

Predoctoral researcher
Diabetes and Metabolism
Read more
Alejandra Planas Vilaseca

Alejandra Planas Vilaseca

Predoctoral researcher
Diabetes and Metabolism
Read more
Ana Maria Ortiz de Urbina Olive

Ana Maria Ortiz de Urbina Olive

Research assistant
Diabetes and Metabolism
Read more
Angel Michael Ortiz Zúñiga

Angel Michael Ortiz Zúñiga

Postdoctoral researcher
Diabetes and Metabolism
Read more

Projects

TBC

IP: Rafael Simó Canonge
Collaborators: Miriam Izquierdo Sans
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 111758
Reference: PREP2022-000737
Duration: 01/03/2024 - 29/02/2028

Ministerio de Ciencia

Mechanisms of metabolic adaptation after weight loss in obesity. Clinical phenotyping and therapeutic approach.

IP: Andreea Ciudin Mihai
Collaborators: Nuria Vallejo Camazón, Cristina Gamez Cenzano, Eduardo Ródenas Alesina, Ana Marti Delgado, Fiorella Ximena Palmas Candia, Bruno Garcia del Blanco, Ana Belén Méndez Fernández, Toni Soriano Colomé, Aleix Olivella San emeterio, Marta Comas Martinez, Alvaro Calabuig Goena, Enzamaría Fidilio Meli
Funding agency: Instituto de Salud Carlos III
Funding: 165000
Reference: PI23/01209
Duration: 01/01/2024 - 30/06/2028

Funciones Alternativas de la Sex Hormone-Binding Globulin: Mecanismos Moleculares y Papel en Fisiología y Fisiopatología

IP: David Martinez Selva
Collaborators: Maria Teresa Salcedo Allende, Lorena Ramos Pérez, Pablo Gabriel Medina, Pilar Costa Forner
Funding agency: Instituto de Salud Carlos III
Funding: 190000
Reference: PI23/00544
Duration: 01/01/2024 - 31/12/2026

New Biomarker for NAFLD and NASH Development and Progression

IP: David Martinez Selva
Collaborators: -
Funding agency: Fundació "La Caixa"
Funding: 50000
Reference: CAIXAIMPULSE/CI23-10154
Duration: 12/12/2023 - 11/08/2026

Blog

News

The families of the professionals had the opportunity to visit the facilities and discover how we work at the institution.

The document provides recommendations for identifying people who are candidates for these treatments and for guiding their implementation and follow-up in clinical practice.

The publications update the pharmacological management guideline for obesity and its complications and present the first European comprehensive management guideline for patients with obesity treated with medications.